{"id":"b-arm-flag-ida","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (neutropenia, thrombocytopenia, anemia)"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Neurotoxicity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"FLAG-IDA combines three cytotoxic agents: fludarabine (a purine analog that inhibits DNA synthesis), cytarabine (a pyrimidine analog that incorporates into DNA), and idarubicin (a topoisomerase II inhibitor that causes DNA strand breaks). Together, these agents work synergistically to kill rapidly dividing leukemic cells by overwhelming their DNA repair mechanisms and triggering programmed cell death.","oneSentence":"FLAG-IDA is a chemotherapy combination regimen that uses fludarabine, cytarabine, and idarubicin to induce apoptosis in leukemic cells through DNA damage and inhibition of DNA synthesis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:03:25.069Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia (AML), relapsed or refractory"},{"name":"Acute lymphoblastic leukemia (ALL), relapsed or refractory"}]},"trialDetails":[{"nctId":"NCT03257241","phase":"PHASE3","title":"A PALG Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in AML Patients ≤ 60 Years Old","status":"UNKNOWN","sponsor":"Polish Adult Leukemia Group","startDate":"2017-07-03","conditions":"Acute Myeloid Leukemia","enrollment":582},{"nctId":"NCT02272478","phase":"PHASE2, PHASE3","title":"Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations","status":"UNKNOWN","sponsor":"Cardiff University","startDate":"2014-10-30","conditions":"Acute Myeloid Leukaemia, Myelodysplastic Syndrome","enrollment":1600}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Fludarabine, Cytarabine, Idarubicin, G-CSF"],"phase":"phase_3","status":"active","brandName":"B arm (FLAG-IDA)","genericName":"B arm (FLAG-IDA)","companyName":"Polish Adult Leukemia Group","companyId":"polish-adult-leukemia-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FLAG-IDA is a chemotherapy combination regimen that uses fludarabine, cytarabine, and idarubicin to induce apoptosis in leukemic cells through DNA damage and inhibition of DNA synthesis. Used for Acute myeloid leukemia (AML), relapsed or refractory, Acute lymphoblastic leukemia (ALL), relapsed or refractory.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}